


PHARMACEUTICAL 2020










PHARMACEUTICAL 2020





The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 360% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is 93%, being 396% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	13,709,600
Cost of Goods Sold	4,721,200
Intangible Assets	10,297,400
Liabilities, Current	11,775,200
Liabilities, Non-Current	24,811,800
Other Assets	7,406,200
Other Compr. Net Income	-783,400
Other Expenses	1,151,600
Other Liabilities	0
Other Net Income	3,680,500
Property and Equipment	7,872,900
Research and Development	5,595,000
Revenues	22,319,500
Selling, General and Administrative Expense	6,213,800

Output Variable	Value in 1000 USD
Assets	39,286,100
Liabilities	36,587,000
Expenses	17,681,600
Stockholders Equity	2,699,100
Net Income	8,318,400
Comprehensive Net Income	7,926,700
Economic Capital Ratio	93%

